SU-E-J-269: Assessing the Precision of Dose Delivery in CBCT-Guided Stereotactic Body Radiation Therapy for Lung and Soft Tissue Metastatic Lesions

2014 ◽  
Vol 41 (6Part10) ◽  
pp. 219-220
Author(s):  
S Parsai ◽  
A Dalhart ◽  
C Chen ◽  
E Parsai ◽  
D Pearson ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Stereotactic Body Radiation Therapy ◽  
Dose Delivery ◽  
Stereotactic Body Radiation ◽  
Metastatic Lesions

Non-surgical Treatments for Lung Metastases in Patients with soft Tissue Sarcoma: Stereotactic Body Radiation Therapy (SBRT) and Radiofrequency Ablation (RFA)

2020 ◽  
Vol 16 ◽  
Author(s):  
Cecilia Tetta ◽  
Maria Carpenzano ◽  
Areej Tawfiq J Algargoush ◽  
Marwah Algargoosh ◽  
Francesco Londero ◽  
...  
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Stereotactic Body Radiation Therapy ◽  
Lung Metastases ◽  
Disease Free Interval ◽  
Stereotactic Body Radiation ◽  
Free Interval ◽  
Disease Free

Background: Radio-frequency ablation (RFA) and Stereotactic Body Radiation Therapy (SBRT) are two emerging therapies for lung metastases. Introduction: We performed a literature review to evaluate outcomes and complications of these procedures in patients with lung metastases from soft tissue sarcoma (STS). Method: After selection, seven studies were included for each treatment encompassing a total of 424 patients: 218 in the SBRT group and 206 in the RFA group. Results: The mean age ranged from 47.9 to 64 years in the SBRT group and from 48 to 62.7 years in the RFA group. The most common histologic subtype was, in both groups, leiomyosarcoma. : In the SBRT group, median overall survival ranged from 25.2 to 69 months and median disease-free interval from 8.4 to 45 months. Two out of seven studies reported G3 and one G3 toxicity, respectively. In RFA patients, overall survival ranged from 15 to 50 months. The most frequent complication was pneumothorax. : Local control showed high percentage for both procedures. Conclusion: SBRT is recommended in patients unsuitable to surgery, in synchronous bilateral pulmonary metastases, in case of deep lesions and in patients receiving high-risk systemic therapies. RFA is indicated in case of a long disease-free interval, in oligometastatic disease, when only the lung is involved, in small size lesions far from large vessels. : Further large randomized studies are necessary to establish whether these treatments may also represent a reliable alternative to surgery.

scholarly journals Stereotactic Body Radiation Therapy (SBRT) for a Patient with a Myocardial Metastasis: A Case Report

2021 ◽  
Vol 28 (1) ◽  
pp. 390-395
Author(s):  
Aneesh Dhar ◽  
Elysia Donovan ◽  
Darryl Leong ◽  
Sebastien J. Hotte ◽  
Anand Swaminath
Keyword(s):  
Radiation Therapy ◽  
Stereotactic Body Radiation Therapy ◽  
Mri Scan ◽  
Distant Disease ◽  
Cardiac Lesion ◽  
Stereotactic Body Radiation ◽  
Metastatic Lesions ◽  
Cardiac Symptoms ◽  
Myocardial Metastasis ◽  
Magnetic Resonance Imaging Mri

Metastatic lesions of the heart are rare but have the potential to cause significant morbidity. We describe the case of a patient with renal cell carcinoma who presented with shortness of breath and palpitations and was found to have a metastatic myocardial lesion causing arrythmia. He received stereotactic body radiation therapy (SBRT) to alleviate symptoms and provide local control. SBRT planning was executed using a four-dimensional computed tomography (4DCT) scan to account for respiratory and cardiac motion. Images from a planning magnetic resonance imaging (MRI) scan and a gated diagnostic MRI scan of the heart were fused with the 4DCT to assist with delineating the tumour. A dose of 30 Gy in five fractions was delivered without incident. The patient’s cardiac MRI at two months post-treatment showed stability of his cardiac lesion. He subsequently died of distant disease progression, without any recurrence of his cardiac symptoms. SBRT may be considered for patients who present with a symptomatic metastatic cardiac lesion.

scholarly journals Feasibility of using stereotactic body radiation therapy for unresectable soft tissue tumors of the trunk

Oncotarget ◽  
2018 ◽  
Vol 9 (45) ◽  
pp. 27851-27857 ◽  
Author(s):  
Eun Kyung Paik ◽  
Mi-Sook Kim ◽  
Chul-Koo Cho ◽  
Hyung Jun Yoo ◽  
Won Il Jang ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Stereotactic Body Radiation Therapy ◽  
Soft Tissue Tumors ◽  
Stereotactic Body Radiation

Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma

2015 ◽  
Vol 51 (5) ◽  
pp. 668-674 ◽  
Author(s):  
Pierina Navarria ◽  
Anna Maria Ascolese ◽  
Luca Cozzi ◽  
Stefano Tomatis ◽  
Giuseppe Roberto D’Agostino ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Stereotactic Body Radiation Therapy ◽  
Lung Metastases ◽  
Stereotactic Body Radiation

SU-E-T-419: To Validate Dose Delivery in Static Field Stereotactic Body Radiation Therapy (SBRT) of Lung Cancer

2013 ◽  
Vol 40 (6Part17) ◽  
pp. 301-301
Author(s):  
CP Joshi ◽  
L Garcia ◽  
T Olding ◽  
K Alexander ◽  
T Owen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Stereotactic Body Radiation Therapy ◽  
Static Field ◽  
Dose Delivery ◽  
Stereotactic Body Radiation
Sign in / Sign up

Export Citation Format

Share Document